A fundamental structural event in the progression of heart failure due to dilated cardiomyopathy is left ventricular (LV) myocardial remodeling. The matrix metalloproteinases (MMPs) are an endogenous family of enzymes which contribute to matrix remodeling in several disease states. The goal of this report is to summarize recent findings regarding the myocardial MMP system and the relation to matrix remodeling in the failing heart. In both experimental and clinical forms of dilated cardiomyopathy (DCM), increased expression of certain species of myocardial MMPs have been demonstrated. Specifically, increased myocardial levels of the gelatinase, MMP-9 has been identified in both ischemic and non-ischemic forms of human DCM. In addition, stromelysin or MMP-3 increased by over four-fold in DCM. The increased levels of MMP-3 in DCM may have particular importance since this MMP degrades a wide range of extracellular proteins and can activate other MMPs. In normal human LV myocardium, the membrane type 1 MMP (MT1-MMP) was detected. These MT-MMPs may provide important sites for local MMP activation within the myocardium. In a pacing model of LV failure, MMP expression and activity increased early and were temporally associated with LV myocardial matrix remodeling. Using a broad-spectrum pharmacological MMP inhibitor in this pacing model, the degree of LV dilation was attenuated and associated with an improvement in LV pump function. Thus, increased LV myocardial MMP expression and activity are contributory factors in the LV remodeling process in cardiomyopathic disease states. Regulation of myocardial MMP expression and activity may be an important therapeutic target for controlling myocardial matrix remodeling in the setting of developing heart failure.
Introduction
that LV remodeling is an important contributory event in the progression to end-stage CHF [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . However, the A central component in the development and progresstructural basis and contributory mechanisms for the sion of congestive heart failure (CHF) is left ventricular changes in LV geometry which occur during the pro-(LV) pump dysfunction. The LV pump dysfunction obgression of CHF are not fully understood. The LV myocarserved with CHF is paralleled by changes in LV geometry, dial fibrillar collagen matrix contributes to the maintenance which is referred to as myocardial remodeling. LV myocarof LV geometry and the structural alignment of adjoining dial remodeling and subsequent chamber dilation have myocytes. Alterations in collagen structure and composibeen associated with increased morbidity and mortality in tion have been reported to occur within the LV myocarpatients with CHF; irrespective of the etiology [1, 2] . dium in several cardiac disease states, which in turn may Moreover, clinical as well as experimental studies suggest influence LV geometry [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . An endogenous family of enzymes responsible for extracellular collagen degradation *Corresponding author. Tel.: 11-843-953-3498; fax: 11-843-953-3499.
Time for primary review 28 days.
are the matrix metalloproteinases (MMPs) [16] [17] [18] . The in CHF. Thus, the identification of MMP species which are purpose of this report is to examine the biology of MMPs involved in cardiac disease states and the mechanisms and to place this proteolytic system in the context of LV which control MMP expression and activation has become remodeling which occurs in end-stage CHF, with particular an area of active research. focus on the dilated cardiomyopathies.
The structure and classification of the matrix 2. The myocardial collagen matrix metalloproteinases
The myocardial fibrillar collagens such as collagen types A generic structure of the MMP enzyme is shown in I and III, ensure structural integrity of adjoining myocytes, Fig. 1 with respect to three common domains: pro-peptide, provide the means by which myocyte shortening is transcatalytic and C-terminal domain. The MMP catalytic lated into overall LV pump function and are essential for domain contains a highly conserved zinc binding region maintaining alignment of myofibrills within the myocyte which may be essential for maintaining enzymatic activity through a collagen-integrin-cytoskeletal-myofibril rela- [18] . This region of the catalytic domain is a common tion. The development of LV dilation in patients and target for the pharmacological development of MMP animals has been shown to result in discontinuity of the inhibitors [34] [35] [36] [37] [38] . MMPs can be broadly categorized into fibrillar collagen network [4, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] . Furthermore, insub-groups based upon specificity and structure. These creased collagen degradation products have been measured sub-groups include the interstitial collagenases, gelatinases, in the plasma of CHF patients and prognostic relationships stromelysins, and membrane type MMPs (MT-MMPs). have been described [19, 20] . The results from these past
The MMP species which may have particular relevance to studies have provided the working hypothesis that changes the LV matrix remodeling process are summarized in Table  in fibrillar collagen structure and support, which primarily 1. occur through degradative pathways, is a structural mechaInterstitial collagenases include MMP-1, MMP-8 and nism by which progressive LV dilation and remodeling MMP-13. MMP-1 cleaves the fibrillar collagens such as occurs with developing CHF [11, 13, [21] [22] [23] [24] [25] [26] [27] [28] .
collagen type-I and -III at specific sites of the collagen molecule [18] . MMP-8 has similar specificity to that of MMP-1, but the key feature of MMP-8 is that it is the 3. Collagen degradation and the matrix predominant form of interstitial collagenase found in metalloproteinases neutrophils. Increased MMP-8 expression and activity are commonly found in inflammatory and wound healing The matrix metalloproteinases (MMPs) are a family of processes [18] . Interestingly, it has been reported that zinc-dependent enzymes which have a high affinity for MMP-8 was detected in samples taken from end-stage extracellular matrix components and therefore play a cardiomyopathic disease [5] . MMP-13 is the predominant fundamental role in tissue remodeling processes [16] [17] [18] .
form of interstitial collagenase found in rodents [18] . More recently, changes in MMP expression profiles and MMP-13 has been identified to be expressed in human activational states have been identified in a number of breast carcinoma and in osteoarthritic chondrocytes [39] . evolving cardiovascular disease states. For example, inUsing immunoblotting techniques [11, 21, 23 ,26], we obcreased MMP activity has been identified to occur in aortic served a strong signal for MMP-13 in normal human aneurysms and has been postulated to significantly contribmyocardial samples (Fig. 2) . Thus, all of the interstitial ute to dilation and progression of the aneurysm [29, 30] . In collagenases have been detected in human LV myocarcoronary artery disease, atherosclerotic plaque rupture has dium. MMP-2 and MMP-9 possess the capacity to degrade been shown to be temporally associated with heightened a number of interstitial proteins [16] [17] [18] . Both MMP-2 and MMP activity within the lesion [31] [32] [33] . Finally, increased MMP-9 have been demonstrated previously to be highly MMP expression and activation accompany LV remodeling expressed in LV myocardium [11, 21, 23, 26] . Moreover, a Fig. 1 . Generic structure of the MMP zymogen. The MMP propeptide sequence contains a small signalling peptide which directs newly synthesized MMP to the cell membrane for secretion into the extracellular space. The propeptide contains a highly conserved amino acid sequence (PRCGVPD) which 21 maintains enzymatic latency. The catalytic domain contains three histidines that bind zinc (Zn ) which is necessary for proteolytic activity. The C-terminal domain is unique between MMP species as this domain contains extracellular protein binding sites which contribute to MMP enzyme specificity (Adapted from Ref.
[18]). (Fig. 3 ) [25] . Thus, [40, 41] . Another important class of MMPs with respect to it is likely that LV myocytes are an important source of MMP activation are the MT-MMPs. While there are now MMPs within the myocardium and therefore have the four species of MT-MMPs which have been identified, capacity to directly participate in the LV matrix remodeling MT1-MMP has been clearly shown to participate in the process through the expression, synthesis and release of MMP activational process in a number of cell systems MMPs.
[ [42] [43] [44] . Using immunoblotting techniques, we were able The stromelysins, such as MMP-3, degrade a large to identify MT1-MMP in normal human LV myocardial number of extracellular substrates such as collagen and preparations (Fig. 2) . The relevance of MMP-3 and MT1-basement membrane components [18, 40, 41] . MMP-3 is MMP expression within the LV myocardium with respect ubiquitously expressed in a number of tissues and by a to MMP activation and matrix degradation is discussed in large number of cell types. One of the unique features of a subsequent section. Fig. 2 . Normal human LV myocardial extracts were subjected to immunoblotting as described previously [21] . A monoclonal antibody solution (1.0 mg / ml) for MMP-13 (MAB3321, Chemicon), MT1-MMP (MAB3317, Chemicon), or EMMPRIN (MAB1354, Chemicon) was used. A positive control was included in all immunoblots (MMP-13: CC068, MT1-MMP: CC1042, Chemicon; Human Breast Cancer Preparation for EMMPRIN). A robust signal was observed for the MMP-13 and for MT1-MMP indicating that these MMP species exist in human LV myocardium. A strong positive signal for the MMP inducer protein EMMPRIN was also observed. Fig. 3 . Normal isolated human LV myocytes were subjected to immunofluorescent staining for MMP-2 and examined under phase contrast microscopy (left panels) and under FITC excitation (right panels). The isolated myocytes used for immunostaining demonstrated a normal rod-shaped morphology and sarcomeric banding could be readily appreciated. A strong immunofluorescent signal was detected in myocytes for MMP-2. Substitution with non-immune antisera abolished this fluorescent staining pattern (negative control). These results suggest that LV myocytes have the capacity to synthesize MMPs. Reproduced from Ref. [25] with permission from the American Physiological Society.
Control of matrix metalloproteinase expression
and cytokines, such as tumor necrosis factor-a (TNF-a) which stimulate the production of proto-oncogenes, have In tumor cell lines, MMP mRNA has been shown to be been demonstrated to increase MMP transcription in upregulated by bioactive peptides and cytokines [45, 46] . several cell systems [46, [50] [51] [52] . Increased levels of TNF-a Protein kinase C (PKC) induces MMP transcription in have been reported in patients with LV failure and TNF-a several cell systems [45, [47] [48] [49] . CHF is accompanied by levels are associated with disease progression [53] [54] [55] [56] [57] . A increased circulating levels of catecholamines, angiotensinpast study demonstrated that increased circulating TNF-a II and endothelin, which in turn can cause a receptor levels in normal rats caused LV remodeling and subsequent mediated increase in PKC. MMP genes contain response pump dysfunction [24] . Moreover, these pathophysiologielements such as TRE, which binds proto-oncogene prodcal relevant concentrations of TNF-a caused alterations in ucts of the fos and jun family [45, 48] . Bioactive peptides the extracellular matrix such as diminished collagen con-fluence and continuity of the fibrillar matrix between provide for a local MMP activation system which will myocytes [24] . Thus, one intriguing hypothesis is inresult in focalization of MMP activity and therefore creased levels of TNF-a can induce MMP expression in extracellular remodeling. Our preliminary results have LV myocytes which in turn cause changes in extracellular demonstrated that MT1-MMP exists in normal human LV matrix structure thereby facilitating the LV remodeling myocardium ( Fig. 2 ) and may be an important system for process in CHF.
the activation of MMPs within the myocardium. In certain While extracellular stimuli induce MMP expression, cell systems, it has been demonstrated that cytokines such endogenous control systems which regulate MMP tranas TNF-a upregulate MT1-MMP levels [44, 52] . Whether scription remain poorly understood. However, more recent increased cytokine levels and other bioactive peptides studies have identified a novel 58-kDa protein, called which occur in developing CHF influence myocardial MTextracellular matrix metalloproteinase inducer MMP expression and activity remains unknown. (EMMPRIN) on the cell surface of specific tumor cell
The tissue inhibitors of MMPs (TIMPs) bind to MMPs lines which caused the induction of MMP expression in a stoichiometric 1:1 molar ratio and therefore form an [58, 59] . Moreover, we have identified that EMMPRIN important endogenous system for regulating MMP activity exists in normal human LV myocardium (Fig. 2) . Thus, an in vivo [18, 41, [60] [61] [62] . TIMPs bind to the active site of the important local induction system for MMPs exists within
MMPs by blocking access to the collagen substrate. TIMPthe human LV myocardium which may be an important 1 forms a complex with several MMPs which include regulatory process for MMP expression. The potential role MMP-1 and MMP-9. TIMP-4 has been recently characterof this local MMP induction system in the progression of ized as having a relatively unique expression pattern [61] . CHF warrants further study. Specifically, the only organ which was observed to have a high expression pattern for TIMP-4 was the myocardium [61] . However whether TIMP-4 possesses different MMP 6. Activational control of MMPs inhibitory activity within the myocardium remains unclear. 40, 41] . Following the initial proteolytic cleavage by serine proteases, conversion to the fully active MMP 7. Pharmacological development of matrix can be achieved through a final common enzymatic metalloproteinase inhibitors pathway requiring stromelysin (MMP-3) [40, 41] . Thus, an important regulatory step in overall MMP activation Studies have clearly shown a positive correlation beinvolves the expression and activational state of MMP-3.
tween MMP activity and metastatic tumor behavior and The critical role that MMP-3 plays in the activation of key inflammation [16] [17] [18] . Accordingly, a number of synthetic MMP species is indicated in Table 2. MMP inhibitors have been developed with a broad range While a proteolytic cascade can result in fully active of specificity as well as compounds which have very select MMPs, the MT-MMPs have been shown to be an imspecificity for MMP species [34] [35] [36] [37] [38] . Current targets for portant site for MMP activation in tumor cell systems MMP inhibition include corneal ulcerations, malignant [41] [42] [43] [44] . MT1-MMP has been clearly shown to participate ascites, tumor metastases and arthritis [63] [64] [65] [66] . In initial in the MMP activational process in a number of cell efforts, a Parke-Davis compound with global MMP inhibsystems [44] . Specifically, pro-MMP-2 will bind to a itory activity (PD166793) was evaluated in a model of specific extracellular domain of MT1-MMP and result in CHF and the results are summarized in the following full activation of MMP-2 [43, 44] . Moreover, MMP-13 is section [27] . This MMP inhibitor demonstrated inhibitory directly activated by MT1-MMP [41] . The MT-MMPs activity against a number of MMP species potentially relevant to myocardial matrix remodeling but was not lagen degradative pathways occur within the LV myocaractive against other proteolytic systems [27]. Thus, orally dial interstitium during the progression of CHF. active MMP inhibitors can be successfully constructed
In order to determine whether MMP expression is which do not possess activity against other proteolytic induced in human CHF, LV myocardial extracts from systems relevant to the CHF process. Recent evidence has normal and DCM samples were subjected to immunoaccumulated that global MMP inhibition which results in blotting for MMP-1, 2, 3 and 9 as described previously direct MMP-1 inhibition, caused undesirable systemic [21, 26] . Increased levels of MMP-9 were observed in these effects [63, 64] . Specifically, non-selective MMP inhibition DCM samples. Interestingly, MMP-1 levels were reduced using hydroxymate constructs such as the British Bio-Tech in the end-stage cardiomyopathy samples when compared compounds [64] [65] [66] , can induce muscle and joint pain to normals. However, a significant and robust signal for [63, 64] . An alternative approach would be to inhibit the MMP-3 was observed with DCM (Fig. 5) . The increased activational process of MMPs through selective inhibition expression of MMP-3 with DCM would potentially conof MMP-3, but to actually 'spare' direct inhibitory actions tribute to a cooperative, step-wise process necessary in on the MMP-1 enzyme. The development of more selecorder to achieve fully active MMPs within the myocardium tive MMP inhibitors will be of significant importance if [40, 41] . these are to be considered for use in cardiovascular disease states where chronic treatment will likely be required.
9. LV myocardial matrix metalloproteinase activity in CHF
LV myocardial matrix metalloproteinase expression
The most common approach for the assessment of MMP in CHF activity in tissue is through the extraction of the samples and performing in vitro assays [5, 11, 17, [21] [22] [23] [25] [26] [27] . Several studies have demonstrated increased MMP The tissue extracts are often first electrophoretically sepaexpression and abundance in experimental models of CHF rated and then exposed to MMP substrates in order to and with end-stage cardiomyopathic disease in humans assess proteolytic activity. For example, MMP zymog- [5, 21, 22, 26, 67] . Initial studies by this laboratory were raphy consists of electrophoretic gels which are impregfocused upon determining whether and to what degree nated with an MMP substrate and the tissue samples run MMP species expression and activation were altered with into the gel [11, 21] . Proteolytic activity within the tissue the progression of CHF. Since LV dilation and remodeling extracts can then be identified at different molecular are important sequelae and can actually precede the weights. LV myocardial MMP gelatinase activity was development of LV pump dysfunction, the goal was to examined in pacing CHF samples using digital zymogrelate potential changes in MMP expression and activity to raphic methods (Fig. 4) [11, 21] . These studies demonthe LV remodeling process in CHF. For these studies, we strated a time-dependent increase in MMP zymographic used a model of rapid pacing induced CHF in pigs which activity during the progression of pacing CHF. More produces the clinical phenotype of CHF [9- importantly, MMP zymographic activity was increased 11, 14, 15, 27, 68] . We have demonstrated previously that this early in the time course of pacing CHF, which preceded model of chronic pacing produces well defined, predictsignificant changes in LV myocyte contractile dysfunction able, and progressive LV dilation and matrix remodeling [11] . [10, 11, 14, 15 ]. The pacing model of CHF causes bivenStudies from this laboratory and others have clearly tricular dilation and dysfunction similar to that of dilated demonstrated that increased MMP zymographic activity cardiomyopathy. However, this review will focus on the occurs in end-stage DCM [21, 22, 26] . Using LV myocardial LV with respect to matrix remodeling and MMP activity.
extracts from non-ischemic and ischemic origin, signifiThe relative abundance of MMPs was examined in LV cantly greater LV myocardial zymographic MMP activity myocardial extracts during the development of pacing CHF was observed (Fig. 6) . Thus, in both forms of carby immunoblotting for MMP-1, 2, and 3 [11, 23] . A strong diomyopathy, LV myocardial MMP activity is increased immunoreactive signal corresponding to MMP-1, 2 and 3 and potentially contributes to the remodeling process was detected in LV myocardial extracts (Fig. 4) . Denwhich invariably occurs in these cardiac disease processes. sitometry revealed a time dependent increase in MMP However, it remains unclear whether different MMP abundance with the progression of pacing CHF. At day 7 species expression occurs in these two different etiologies of pacing, a robust increase in MMP-3 and MMP-2 was of cardiomyopathic disease. It is very likely that different observed. The early increase in MMP-3 expression would extracellular stimuli will induce different portfolios of potentially contribute to the activational cascade for a MMP expression within the myocardium. For example, number of MMPs. Thus, an early event in the progression this laboratory has recently reported that differential of pacing CHF was increased LV myocardial MMP abunexpression and activation occurs following the induction of dance. These findings demonstrated that changes in coleither an acute pressure or volume overload stimulus [69].
Fig. 4. (A) Immunoblotting was performed on LV myocardial extracts for interstitial collagenase (MMP-1), 72-kDa gelatinase (MMP-2)
, and stromelysin (MMP-3) taken from control (time 0) and with each week of chronic rapid pacing. A time-dependent increase in MMP abundance was observed following 7 and 14 days of pacing with a strong signal observed after 3 weeks of pacing. A positive control (1) for the MMPs was included as described previously [11, 27] . (B) MMP zymographic activity was examined in LV myocardial extracts using gelatin as a proteolytic substrate in control samples and with each week of chronic rapid pacing. A positive control from an HT1080 cell line (1) was used as described previously [11, 27, 31] . In the zymogram, proteolytic activity was observed in LV myocardial extracts in the 50-90-kDa region. Under non-activated and activated conditions, MMP zymographic activity was increased in the rapid pacing samples. Moreover, a robust increase in MMP zymographic activity occurred by 7 days of pacing indicating suggesting that an early increase in MMP myocardial activity occurred during the development of pacing CHF. Reproduced from Ref. [11] with permission from the American Heart Association.
Specifically, the induction of a volume overload due to activity without electrophoretic separation [27] . With the mitral regurgitation was associated with increased myocardevelopment and application of MMP inhibitors, improved dial expression of MMP-3 [69] . In contrast, the induction methods for measuring indices of MMP tissue activity will of a pressure overload due to aortic stenosis was not be necessary if the local effects of these MMP inhibitors accompanied by an induction of MMP-3. Thus, different are to be rigorously examined. Nevertheless, measurements wall stress patterns may invoke distinct patterns of MMP of zymographic activity provide evidence that the inexpression, which in turn would contribute to the type of creased potential for heightened MMP activity occurs in LV matrix remodeling which occurs during adaptation to a failing myocardium. prolonged volume or pressure overload stimulus.
One potential mechanism for the increased myocardial An important consideration regarding the LV myocardial MMP activity with end-stage CHF is a loss of endogenous zymographic measurements is that these are in vitro inhibitory control. A study by Li et al. [22] provided studies which cannot completely represent the degree of in evidence to suggest that changes in the MMP/ TIMP vivo MMP activity. For example, using in vitro assay stoichiometric ratio occurred with end-stage carsystems, local inhibitors such as TIMPs may dissociate diomyopathic disease. Specifically, TIMP-1 and TIMP-3 from MMP binding sites during myocardial sample prepalevels were reduced in cardiomyopathic samples whereas ration. Furthermore, in vitro assay systems are performed TIMP-2 levels were unchanged when compared to conunder optimal conditions with purified substrates. More trols. It has been demonstrated previously that TIMP-1 and recently, we have described an MMP antibody capture TIMP-2 expression are differentially regulated by a numassay which allowed for quantitation of myocardial MMP ber of external stimuli [62] . For example, cytokines such as TNF-a can modify the expression of TIMP-1 through tion in MMP-1 levels in the DCM samples [21] . These the induction of nuclear transcription factors, but TIMP-2 results suggest that reduced MMP/ TIMP complex formaexpression appears to be unaffected by cytokine stimulation may occur in cardiomyopathic disease states which in tion [46, 48, 62] . Thus, differences in TIMP-1 and TIMP-2 turn would contribute to increased myocardial MMP levels may occur in the setting of increased myocardial activity. neurohormone and cytokine production. The different TIMPs exhibit species selectivity with respect to forming complexes with pro-MMPs. For example, TIMP-1 binds 10. Matrix metalloproteinase inhibition and with the pro-peptide sequence of MMP-9 and TIMP-2 developing CHF binds to pro-MMP-2 [18, 44, 60] . The TIMP binding domain for the pro-MMPs is located at the C-terminal of the The studies outlined above identified increased myocarTIMPs and is distinct from the domain which inhibits dial MMP expression and activity with the development of activated MMPs [18, 41] . It has been demonstrated that severe CHF. However, whether heightened MMP activity pro-MMP-2 / TIMP-2 complexes can be activated in vitro contributes to the LV matrix remodeling which occurs by organomercurial agents in the same fashion as free during the evolution of the CHF process remained to be pro-MMP-2 [18, 41] . Thus, formation of pro-MMP/ TIMP established. Accordingly, the goal of a recently completed complexes does not necessary prevent activation of the study was to determine whether chronic MMP inhibition complexed MMP. These pro-MMP/ TIMP complexes may would influence LV geometry and function in the setting of reflect additional functions of TIMPs in controlling MMP developing CHF [27] . This study was designed in order to activational state and stability.
test the hypothesis that interruption of myocardial MMP In a past study, Li et al. [22] reported a reduction in activity will reduce the LV dilation which invariably occurs TIMP-1 abundance with in end-stage cardiomyopathy. In in the pacing model of CHF. The global MMP inhibitor order to begin to address whether this reduction in TIMP-1 PD166793, as discussed in the previous section was used levels may result in alterations in inhibitory control, we in the pig model of pacing CHF [27] . Representative serial measured MMP-1 / TIMP-1 complex formation in normal LV echocardiographic recordings are shown in Fig. 8 . The and DCM LV myocardial samples (Fig. 7) [21, 26] . In both degree of LV dilation and posterior wall thinning which non-ischemic and ischemic cardiomyopathy, an absolute occurs in a time dependent fashion with chronic rapid reduction in MMP-1 / TIMP-1 complex formation occurred.
pacing was attenuated with MMP inhibition. After 21 days One contributory factor for the reduction in the levels of of pacing, the degree of LV dilation had significantly this specific MMP/ TIMP complex was the absolute reducprogressed without treatment and was accompanied by control sections, the fibrillar collagen weave could be readily appreciated between adjoining myocytes. With pacing CHF, the collagen weave surrounding individual myocytes appeared reduced and disrupted. In the rapid pacing and MMP inhibition group, the fibrillar collagen weave appeared increased between adjoining myocytes. the myocardial fibrillar collagen matrix have been implicated to influence LV myocardial stiffness characteristics. reduced pump function and posterior wall thickness. With
In this past study, indices of LV chamber and myocardial concomitant MMP inhibition, the degree of LV dilation stiffness were increased when compared to untreated CHF was attenuated and LV pump function improved. The values [27] . Since LV myocardial stiffness reflects intrinsic reduction in LV volumes and the attenuation of wall material properties of the myocardium itself, then this thinning with MMP inhibition resulted in a reduction in LV increase in myocardial stiffness with MMP inhibition was peak wall stress [27] . In isolated myocyte studies, contraclikely due changes in myocardial collagen content and tility was reduced to an equivalent degree in both pacing structure. Thus, while MMP inhibition reduced LV groups irrespective of MMP inhibition treatment. These chamber dimensions during the development of pacing observations suggested that the basis for the improvement CHF, this was accompanied by potentially negative effects in LV pump function with MMP inhibition was primarily on LV chamber compliance. However, it must be recogdue to beneficial effects on LV geometry.
nized that this study used a high dose of a non-selective LV myocardial specimens from the study outlined above MMP inhibitor. More recent studies from this laboratory were prepared for light and scanning electron microscopy.
have demonstrated that combined angiotensin converting Representative micrographs are shown in Fig. 9 for enzyme and MMP inhibition reduced LV chamber dimencontrol, pacing CHF and CHF with MMP inhibition. In sions in pacing CHF without an associated increase in Fig. 8 . Representative LV echocardiographic recordings taken at each week of rapid pacing, with (right panels) and without (left panels) concomitant MMP inhibition (MMPi). LV size and function were equivalent in both pigs under baseline, pre-pacing conditions. After 7 days of rapid pacing, significant LV dilation occurred in the untreated group and was associated with diminished LV posterior wall motion. After 21 days of rapid pacing, the degree of LV dilation had significantly progressed in the untreated pig and was accompanied by significantly reduced pump function. In the pig concomitantly treated with MMP inhibition during the pacing protocol, the degree of LV dilation was reduced and LV pump function was improved. Reproduced from Ref.
[27] with permission from the American Heart Association.
myocardial stiffness properties [70] . Since LV diastolic activity within the LV myocardium. Moreover, these results dysfunction forms an important component of CHF, then provide proof of concept that the use of pharmacological modulation of MMP activity will need to be carefully MMP inhibitors will alter the course of a developing CHF evaluated with respect to alterations in myocardial stiffness process. In a myocardial infarction model in mice, Rohde properties. et al. [28] demonstrated that MMP inhibition attenuated The results detailed above demonstrated that a contributthe LV dilation which occurred in the early post-infarction ory mechanism for the LV remodeling which occurs during period. Thus, it is likely that increased MMP expression the progression of the CHF process is heightened MMP and activation directly contribute to the LV matrix re- Fig. 9 . Alterations in the myocardial extracellular matrix occurred with the development of pacing induced congestive heart failure (CHF) as described previously [9] [10] [11] 27 ]. These changes in the extracellular matrix could be influenced by matrix metalloproteinase inhibition (CHF / MMPI). Top panels: left ventricular myocardial sections stained with picro-sirius from control, with pacing CHF, and pacing CHF with concomitant treatment with MMPI. The fibrillar collagen weave appeared reduced and disrupted with CHF and was normalized or actually increased with MMPI. Bottom panels: scanning electron microscopy revealed a well organized fibrillar collagen weave in control sections which was disrupted in CHF and appeared to be increased with MMPI (Top and bottom panel bars510 and 1 mm, respectively).
modeling process in a number of cardiac disease states development of high throughput pharmacological screenwhich can potentially accelerate the development of LV ing, the development of potent and selective pharmacopump dysfunction.
logical MMP inhibitors has accelerated and eclipsed our knowledge of MMP biology within the myocardium. Mouse models have been created with alterations in the 11. Summary Most current therapies for CHF do not retard or reverse the underlying cause for the LV dysfunction, and therefore the LV failure continues to progress with the ultimate demise of the patient. The statistics regarding the development of CHF in the US patient population are unsettling. Specifically, approximately one-half million patients develop CHF each year and the incidence has been predicted to increase significantly in the next 10 years worldwide. With the beginning of the new millennium, it may be appropriate to review the development and treatment of CHF (Fig. 10) . A transition in the philosophy and treatment of CHF has occurred in which recognition that modulating the physical and biochemical environment which surrounds the failing LV does not completely retard 
